|
3.1 Tabac
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
5. Traitements
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Pfizer Versus BMS, Since 1989 [In the Pipeline]
|
|
|
|
|
|
Pfizer
has been a massively inefficient research organization. The disruptions
from all those mergers are surely a big part of the problem, as is the
sheer size of the company. Changing the entire course of R&D there,
though, even if you knew just what to do, would disrupt things yet
again. Pfizer is in a hole, folks.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
Drug approvals at 19-year high belie industry challenges [Reuters]
|
|
|
|
|
|
2015
was a good year for innovation in medicine with the U.S. Food and Drug
Administration approving 45 novel drugs, four more than in 2014 and the
most since the all-time record of 53 set in 1996. Across the Atlantic,
the European Medicines Agency recommended 93 new products, including
generics, up from 82 in 2014.
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
5.9.4 AACR - poumon
|
|
|
Advancing Lung Cancer Research [CANCER RESEARCH Catalyst]
|
|
|
|
|
|
The
focus of this Fourth AACR-IASLC International Joint Conference is “Lung
Cancer Translational Science from the Bench to the Clinic,” and
attendees will hear about the most up-to-date advances across the
spectrum of lung cancer research.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.6 Publications
|
|
|
How to increase your Impact Factor by 40% [Brembs Blog]
|
|
|
|
|
|
It
continues to be an embarrassment for science that we rely on such a
blatantly anti-scientific number for our hire-and-fire decisions and it
spells trouble for the generation of scientists who are to come of this
system.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|